Georgia's Online Cancer Information Center

Rhabdomyosarcoma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Rhabdomyosarcoma
Cancer Type = Rhabdomyosarcoma
There are currently 5 active Rhabdomyosarcoma clinical trials in Georgia.
1.
NCORP Trial
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI, Torisel, NSC# 683864, IND#122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Cancer Type
Bone and Soft Tissue (including Sarcoma), Rhabdomyosarcoma
NCT ID
NCT02567435
Protocol IDs
ARST1431
NCI-2015-01644
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
The Medical Center of Central Georgia
Macon
Oncology Research Nurse
4786331738
2.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1 / 2 / 3 / 4 Alterations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCT ID
NCT03210714
Protocol IDs
APEC1621B
APEC1621B
NCI-2017-01159
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
3.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCT ID
NCT03213704
Protocol IDs
APEC1621A
APEC1621A
NCI-2017-01264
APEC1621A
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
4.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCT ID
NCT03233204
Protocol IDs
APEC1621H
APEC1621H
NCI-2017-00766
APEC1621H
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
5.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCT ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
Treatment Sites (1)
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.